Viking Therapeutics, Inc. (NASDAQ:VKTX) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2017 Annual Meeting of Stockholders (the Annual Meeting) of
Viking Therapeutics, Inc. (the Company) was held on May 23, 2017.
At the Annual Meeting, the Companys stockholders elected the
Class II director nominees of the Company and ratified the
selection of Marcum LLP as the Companys independent registered
public accounting firm for its fiscal year ending December 31,
2017 (together, the Proposals). Each Proposal is described in
detail in the Companys definitive proxy statement for the Annual
Meeting that was filed with the U.S. Securities and Exchange
Commission on April 7, 2017. As of April 3, 2017, the record date
for the Annual Meeting, 23,925,425 shares of the Companys common
stock were issued and outstanding. The final votes on the
Proposals presented at the Annual Meeting are as follows:

Proposal 1. Election of Class II Director Nominees

J. Matthew Singleton and Stephen W. Webster were each elected as
Class II directors at the Annual Meeting to serve until the
Companys 2020 Annual Meeting of Stockholders, and until his
respective successor is duly elected and qualified. The final
voting results were as follows:

Proposal 2. Ratification of the Selection of the Companys
Independent Registered Public Accounting Firm

The Companys stockholders ratified the selection by the Audit
Committee of the Board of Directors of the Company of Marcum LLP
as the Companys independent registered public accounting firm for
its fiscal year ending December 31, 2017. The final voting
results were as follows:

About Viking Therapeutics, Inc. (NASDAQ:VKTX)

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Recent Trading Information

Viking Therapeutics, Inc. (NASDAQ:VKTX) closed its last trading session down -0.01 at 1.26 with 79,673 shares trading hands.